On August 4, the U.S. FDA approved Zurzuvae, the first oral medication indicated to treat postpartum depression in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. The approval of Zurzuvae was granted to Sage Therapeutics (SAGE).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
- 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023
- Biotech Alert: Searches spiking for these stocks today
- Reata Pharmaceuticals price target raised to $173 from $85 at Baird
- Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg